We understand that each vaccine project has unique requirements, and we tailor our screening assays to meet your specific needs. Our team of experienced scientists works closely with you to design and optimize the screening assays, taking into consideration the vaccine target, desired immune response, and specific adjuvant characteristics. We offer a range of in vitro and in vivo screening assays to assess adjuvant efficacy and safety.
Our in vitro screening assays allow for the initial evaluation of adjuvant candidates in a controlled laboratory setting. These assays often involve cell-based models to assess the adjuvant’s ability to activate immune cells, stimulate cytokine production, and enhance antigen uptake and presentation. We utilize relevant cell lines and primary immune cells to mimic the physiological conditions and evaluate the adjuvant’s impact on immune responses.
To evaluate adjuvant performance in a more complex and realistic setting, we offer in vivo screening assays using animal models. Our experienced team designs and conducts studies to assess the adjuvant’s ability to enhance immune responses in vaccinated animals. These assays measure antigen-specific antibody titers, cellular immune responses, and other relevant immunological parameters. We adhere to ethical guidelines and animal welfare regulations to ensure responsible and humane use of animals in research.
Our in vitro screening assays allow for the initial evaluation of adjuvant candidates in a controlled laboratory setting. These assays often involve cell-based models to assess the adjuvant’s ability to activate immune cells, stimulate cytokine production, and enhance antigen uptake and presentation. We utilize relevant cell lines and primary immune cells to mimic the physiological conditions and evaluate the adjuvant’s impact on immune responses.
In addition to evaluating adjuvant efficacy, we also conduct safety and toxicity assessments as an integral part of our screening services. We monitor for potential adverse effects, local and systemic reactions, and overall safety profile of the adjuvant candidates. Our team follows rigorous protocols to ensure the safety of the vaccine formulation and minimize potential risks.
Our team of experts provides comprehensive data analysis and interpretation for adjuvant screening results. We utilize advanced statistical analysis tools and visualization techniques to assess adjuvant performance and identify the most promising candidates for further development. We deliver detailed reports summarizing the findings and assisting you in making informed decisions for your vaccine development program.
We prioritize confidentiality and understand the importance of protecting your intellectual property. We work under strict confidentiality agreements and provide a collaborative approach to ensure a seamless partnership. Your research and data are handled with the utmost professionalism and integrity.
CD-1 mice were vaccinated with SARS-CoV2 RBD Antigen and complexed with three different Advax adjuvants from Vaxine intramuscularly. Terminal sera from vaccinated mice show varying neutralization titers against several variants of concern (VoC) in pseudovirus neutralization assay.
In vitro assays are experiments conducted outside of a living organism, typically using isolated cells, tissues, or biochemical components.
